Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says

Phase 3TilrekimigPositive

AI Analysis

Summary

UBS identifies Pfizer's Tilrekimig Phase 3 program as a potential upside driver for the company. The analyst commentary suggests positive expectations regarding the program's potential value.

Clinical Trial Data

Phase

Phase 3

Importance:3/10

Sentiment:

0.50

Phase 3clinical developmentanalyst commentary

Related Companies

$PFE

Read the original article

Published by yahoo_finance on September 28, 2026 3:52 PM

Read Original